

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 98,164-A24	Serial No. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Wolff	
		Filing Date:	Group:
		Concurrently Herewith	


U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate
KG	5,209,933	5/11/93	MacFarlane et al.	_____	_____	
	4,567,264	1/28/96	Kluge et al.	_____	_____	
	5,472,707	12/5/95	Samuels et al.	_____	_____	
	5,506,229	4/9/96	Dow et al.	_____	_____	
KG	5,670,171	9/23/97	Santus et al.	_____	_____	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
KG	WO 94/26266	11/24/94		_____	_____		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KG	Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 99:5-6, 1990.
KG	Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect of ischaemic myocardium. Eur J Clin Pharmacol 38:111-114, 1990.
EXAMINER	
DATE CONSIDERED	3.17.01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 98,164-A24	Serial No. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Wolff	
		Filing Date: Currently Herewith	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KG		Lodge JPA, Lam FT, Perry SL, Giles GR. Ranolazine - a new drug with beneficial effects on renal preservation. Transplantation 50:755-759, 1990.
		Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β -blocker or diltiazem. J Cardiovasc Pharmacol 20:131-138, 1992
		Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of α_1 -adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol 21:869-873, 1993
		Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 109:748-750, 1993
		Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR. Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 24:921-928, 1994.
		Gralinski MR, Black SC, Kilgor KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovascular Research 28:1231-1237, 1994
		Hayashida W, Eyll CV, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovascular Drugs and Therapy 8:741-747, 1994.
		Thadani U, Exekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 90:726-734, 1994
		Herron WJ, Eadie J, Penman AD. Estimation of ranolazine and eleven Phase I metabolites in human plasma by liquid chromatography - atmospheric pressure chemical ionisation mass spectrometry with selected -ion monitoring. Journal of Chromatography A 712:55-60, 1995
		Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Communications in Mass Spectrometry 9:1418-1430, 1995
		Wyatt KM, Skene C, Veitch K, Hue L, McCormack JG. The anti-anginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochemical Pharmacol 50:1599-1606, 1995
		Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 118:249-254, 1996
		Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28:341-350, 1996.
ICG		McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135-142, 1996
EXAMINER 		DATE CONSIDERED 3.17.04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 98,164-A24	Serial No. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Wolff	
		Filing Date: Currently Herewith	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


106		McCormack JG, Baracos VE, Barr R, Lopaschuk GD. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. Am Physiol Society, 905-910, 1996.
1		Wang JX, et al., "Antianginal effects of ranolazine in various experimental models of angina." Arzeimittelforschung 1999 Mar; 49(3): 193-9
1		Matsumura H., et al. "Protective effects of ranolazine, a novel anti-ischemic drug on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate." Jpn J Pharmacol. 1998 May; 77(1):31-9
1		McCormack JG, et al., "Ranolazine; a novel metabolic modulator for the treatment of angina." Gen Pharmacol. 1998 May; 30(5): 639-45.
1		Bagger JP, et al., "Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease." Cardiovasc Drugs Ther. 1997 Jul;11(3): 479-84.
106		Aaker A, et al., "Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction." J Cardiovasc Pharmacol. 1996 Sept; 28(3):353-62.

106		Allely MC, Alps BJ, Kilpatrick AT. The effects of the novel anti-anginal agent RS-43285 on [lactic acid], [K ⁺] and pH in a canine model of transient myocardial ischaemia. Biochemical Society Transactions 622 nd Meeting, Leicester 15:1057-1058, 1987
1		Allely MC, Alps BJ. The effects of the novel anti-anginal agent ranolazine (I.D.) in a canine model of transient myocardial ischaemia. Br J Pharmacol 93(Suppl):246P, 1988
1		Brown CM, Clarke B, Dye A, Fraser S, Kenny BA, Kilpatrick AT, Patmore L, Spedding M, Whiting RL. Pharmacological profile of ranolazine, a metabolic modulator active in ischaemia. Br J Pharmacol 93(Suppl):248P, 1988
1		Ferrandon P, Pascall JC, Armstrong JM. Protective effects of the novel anti-ischaemic agent ranolazine (RS-43285) in perfused rat hearts. Br J Pharmacol 93(Suppl):247P, 1988
1		Pouleur H, Hue L, Harlo BJ, Rousseau MF. Metabolic pathways modulation: a new approach to treat myocardial ischemia? Circulation 80, (Supp II):52, 1989
106		Ferrandon P, Chaylat C, Armstrong JM. Free radical scavengers fail to increase the protective effects of ranolazine in isolated working rat hearts after ischemia and reperfusion. Eur J Pharmacol 183:328-329, 1990
EXAMINER 106 <i>KLM-G</i>		DATE CONSIDERED 3-12-94

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 98,164-A24	Serial No. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Wolff	
		Filing Date:	Group:
		Concurrently Herewith	

ABSTRACTS

KG	Ferrandon, P et al. Ranolazine but not allopurinol or dipyridamole reduces the ventricular acidosis and lactate produced by low perfusion flow in isolated rat hearts. Therapie 45:10, 1990
J	Cocco G, Rousseau MF, Bouvy T, Cheron P, William C, Detry JM, Pouleur H. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina pectoris. Eur Heart J 13(Suppl):97, 1992
	Rousseau MF, Cocco G, Bouvy T, Cheron P, William GJ, Detry JMR, Pouleur H. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina pectoris. Circulation 86(Suppl I):2843, 1992.
	Rousseau MF, Van Eyll C, Van Mechelen H, Harlow BJ, Pouleur H. Novel metabolic ranolazine selectively improves diastolic function in heart failure. Circulation 86(Suppl):375, 1992.
	Collins-Nakai RL, Barr R, Humen D, Lopaschuk GD. Ranolazine stimulates glucose oxidation in isolated working rat hearts. Can J Cardiol 9(Suppl E):104E, 1993
	Rousseau MR, Visser FG, Bax JJ, Dubrey S, Cocco G, Pouleur H, Harris SA, Wolff AA. Ranolazine: anti-anginal therapy with a novel mechanism: placebo controlled comparison versus atenolol. Eur Heart J 15 (Suppl I):95, 1994.
	Rousseau MR, Visser FG, Bax JJ, Noble MIM, Dubrey S, Cocco G, Pasteuning WH, Williams G, Dodds P, Pouleur H. Is modulation of myocardial metabolism as effective as β -blockade in exercise-induced angina? J Am Coll Cardiol 23 (Suppl I):268A, 1994
KG	Smith WB, Chrysant S, Garland WT, Parker TS, Walpole HT, Mokatrin A, Gennevois D, Pepine CJ. A multicenter controlled trial of a novel metabolic active compound (ranolazine) in chronic stable angina patients. J Am Coll Cardio 24A, February 1995
EXAMINER	DATE CONSIDERED
	3-17-94

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.